留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

炎症性肠病的药物治疗现状

卞莹莹 王洁 李安 开国银 陆一鸣

卞莹莹, 王洁, 李安, 开国银, 陆一鸣. 炎症性肠病的药物治疗现状[J]. 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
引用本文: 卞莹莹, 王洁, 李安, 开国银, 陆一鸣. 炎症性肠病的药物治疗现状[J]. 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
Citation: BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002
基金项目: 国家自然科学基金资助项目(30500093,81274162);国家科技部"重大新药创制"专项(2009ZX09103-690);上海市科委生物医药领域科技支撑项目(16431904400);上海市教委科研创新项目(14ZZ077)

The research status of the drug therapy for inflammatory bowel disease

  • 摘要: 炎症性肠病(inflammatory bowel disease,IBD)目前是消化系统疾病的研究热点之一,主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD),其发病机制尚未完全阐明,也尚无针对IBD的有效治疗药物。随着对IBD发病机制的深入研究,出现了一些新型药物和制剂。笔者就IBD及其药物治疗的研究现状作一简要综述。
  • [1] Bernstein CN, Fried M, Krabshuis JH, et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学,2010,15(9):548-558.
    [2] 郭小芹. IL-17/IL-17R通路在炎症性肠病中的免疫调节机制研究[D].北京:中国人民解放军军事医学科学院,2013.
    [3] Rammeart DC, Canling SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet,2007,369(9673):1627-1640.
    [4] Parkes M. The genetics universe of Crohn's disease and ulcerative colitis[J]. Dig Dis,2012,30(Suppl 1):78-81.
    [5] Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea[J]. Scand J Gastroenterol,2010,45(10):1178-1185.
    [6] 牛润章,张兰兰,司依馨. 炎症性肠病的病因及诊治研究进展[J]. 实用医药杂志,2014,31(5):461-463.
    [7] 欧阳钦. 炎症性肠病的病因和发病机制[J]. 实用医学杂志,2003,19(5):448-449.
    [8] Maesla S, Hsu LC, Lin H, et al. Nod-mutation in Crohn's disease potenliales NF-kappaB activity and IL-beta processing[J]. Science,2005,307(5710):734-738.
    [9] 肖 梅,吴正祥. 炎症性肠病的病因研究进展[J]. 安徽医药,2005,9(12):886-889.
    [10] Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeatic alternative[J]. Gastroenterology,1999,116(5):1246-1249.
    [11] 欧阳钦. 炎症性肠病发病机制与治疗研究进展[J]. 中国处方药,2004,23(4):15-19.
    [12] Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induced and perpetuate experimental colitis in rats and mice[J]. Infect Immune,2001,69(4):2277-2285.
    [13] 郭 璟. 4-氨基水杨酸抗炎性肠病衍生物的合成研究[D]. 山西:山西医科大学,2004.
    [14] 黄雪彪. 炎症性肠病的药物治疗[J]. 临床药物治疗杂志,2003,1(4):27-32.
    [15] Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology,1997,113(5):1465-1473.
    [16] Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis[J].Digestion,1984,29(4):204-208.
    [17] 靳宝芬. 4-氨基水杨酸和5-氨基水杨酸抗炎作用及作用机制研究[D].山西:山西医科大学,2014.
    [18] 蒋蔚茹. 炎症性肠病的认识与治疗进展[J]. 上海医药,2010,31(5):207-210.
    [19] 刘 凡. 炎症性肠病药物治疗现状与进展[J]. 沈阳医学院学报,2006,8(4):241-242.
    [20] Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2006,24(2):331-342.
    [21] Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol,2012,24(8):958-964.
    [22] Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma[J]. Gastroenterol,2000,118(6):1018.
    [23] Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopu-rine, mesalamine, or placebo: a 2-year trial[J]. Gastroenterology, 2004,127(3):723-729.
    [24] Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology,2006,130(3):935-939.
    [25] Feagan G, John M. Low-Dose Cyclosporine for the Treatment of Crohn's Disease[J]. Med, 1994,330(26):1846-1851.
    [26] Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis[J]. Clin Gastroenterol,2011,45(2):107-112.
    [27] 崔 静. 炎症性肠病发病机制和治疗方面某些进展[D].郑州:郑州大学,2004.
    [28] 王俊珊,刘占举. 炎症性肠病的诊断和药物治疗相关指南解读[J]. 世界临床药物, 2005,36(12):809-813.
    [29] 黄 瑛,王玉环. 儿童炎症性肠病的药物治疗[J]. 世界临床药物,2009,30(8):459-464.
    [30] 李世荣. 生物靶向药物在炎症性肠病中的应用现状[J]. 中国新药杂志,2010,19(19):1750-1757.
    [31] 杨志红,邓彤斌,王梦明,等. 炎症性肠病的病因学和药物治疗研究进展[J]. 中国药师, 2013,16(6): 905-907.
    [32] 高树娟,施瑞华. 炎症性肠病治疗的新进展[J]. 世界华人消化杂志,2012,36:3742-3747.
    [33] Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology,2011,100(1):75-79.
    [34] Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2010,132(1):1296-1309.
  • 加载中
计量
  • 文章访问数:  3092
  • HTML全文浏览量:  458
  • PDF下载量:  1195
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-09-20
  • 修回日期:  2016-12-03

炎症性肠病的药物治疗现状

doi: 10.3969/j.issn.1006-0111.2017.03.002
    基金项目:  国家自然科学基金资助项目(30500093,81274162);国家科技部"重大新药创制"专项(2009ZX09103-690);上海市科委生物医药领域科技支撑项目(16431904400);上海市教委科研创新项目(14ZZ077)

摘要: 炎症性肠病(inflammatory bowel disease,IBD)目前是消化系统疾病的研究热点之一,主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD),其发病机制尚未完全阐明,也尚无针对IBD的有效治疗药物。随着对IBD发病机制的深入研究,出现了一些新型药物和制剂。笔者就IBD及其药物治疗的研究现状作一简要综述。

English Abstract

卞莹莹, 王洁, 李安, 开国银, 陆一鸣. 炎症性肠病的药物治疗现状[J]. 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
引用本文: 卞莹莹, 王洁, 李安, 开国银, 陆一鸣. 炎症性肠病的药物治疗现状[J]. 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
Citation: BIAN Yingying, WANG Jie, LI An, KAI Guoyin, LU Yiming. The research status of the drug therapy for inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
参考文献 (34)

目录

    /

    返回文章
    返回